Connor, Clark & Lunn Investment Management Ltd.

Position in NUVB — Nuvation Bio Inc.

CIK 1596800 VANCOUVER, A1

Position in NUVB

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$9,978,737

+$4,797,400 QoQ

Shares Held

1,756,820

+45.5% QoQ

Ownership

0.500%

of shares outstanding

% of Portfolio

0.02%

of 13F equity value

Holder Rank

#25

of 242 holders

Holding Since

Dec 2022

12 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $648,992,404 across 104 Biotechnology names. NUVB ranks #18 (1.5% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	135,236	$67,175,777
2	IONS	Ionis Pharmaceuticals Inc	684,236	$54,253,072
3	ARWR	Arrowhead Pharmaceuticals, Inc.	625,569	$50,990,129
4	MIRM	Mirum Pharmaceuticals, Inc.	420,063	$49,176,775
5	REGN	Regeneron Pharmaceuticals, Inc.	42,465	$26,478,625
6	AXSM	Axsome Therapeutics, Inc.	97,698	$23,913,539
7	INSM	INSMED Inc	212,676	$22,675,515
8	VKTX	Viking Therapeutics, Inc.	530,607	$20,698,979

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$9,978,737	1,756,820	+45.5%	Shares	Sole	2026-08-13
2026-03-31	$5,181,337	1,207,771	+529.1%	Shares	Sole	2026-05-11
2025-12-31	$1,720,302	191,998	-54.5%	Shares	Sole	2026-02-10
2024-12-31	$1,123,211	422,260	+6.4%	Shares	Sole	2025-02-10
2024-09-30	$908,525	396,736	+9.0%	Shares	Sole	2024-11-08
2024-06-30	$1,062,661	363,925	-4.8%	Shares	Sole	2024-08-09
2024-03-31	$1,391,135	382,180	+30.1%	Shares	Sole	2024-05-09
2023-12-31	$443,491	293,703	+6.3%	Shares	Sole	2024-02-09
2023-09-30	$370,073	276,174	+69.1%	Shares	Sole	2023-11-13
2023-06-30	$293,909	163,283	+191.3%	Shares	Sole	2023-08-10
2023-03-31	$93,034	56,045	-16.0%	Shares	Sole	2023-05-10
2022-12-31	$128,090	66,714	—	Shares	Sole	2023-02-10
No filing history on record for this holder in this stock.